home / stock / trypf / trypf quote
Last: | $0.047 |
---|---|
Change Percent: | -7.69% |
Open: | $0.0462 |
Close: | $0.047 |
High: | $0.0498 |
Low: | $0.0424 |
Volume: | 138,717 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.047 | $0.0462 | $0.047 | $0.0498 | $0.0424 | 138,717 | 04-25-2024 |
$0.0429 | $0.04 | $0.0429 | $0.04799 | $0.04 | 143,998 | 04-24-2024 |
$0.03685 | $0.04015 | $0.03685 | $0.04015 | $0.03685 | 1,596 | 04-23-2024 |
$0.03595 | $0.03595 | $0.03595 | $0.03595 | $0.03595 | 3,537 | 04-22-2024 |
$0.036 | $0.036 | $0.036 | $0.036 | $0.036 | 1,200 | 04-18-2024 |
$0.0347 | $0.0347 | $0.0347 | $0.0347 | $0.0347 | 795 | 04-17-2024 |
$0.0355 | $0.0355 | $0.0355 | $0.0355 | $0.0355 | 2,255 | 04-16-2024 |
$0.0376 | $0.03 | $0.0376 | $0.0376 | $0.03 | 72,000 | 04-12-2024 |
$0.0253 | $0.0253 | $0.0253 | $0.0253 | $0.0253 | 235 | 04-11-2024 |
$0.025 | $0.02 | $0.025 | $0.03 | $0.02 | 3,691 | 04-10-2024 |
$0.0241 | $0.024 | $0.0241 | $0.0259 | $0.024 | 36,984 | 04-09-2024 |
$0.0154 | $0.0154 | $0.0154 | $0.0154 | $0.0154 | 999 | 04-08-2024 |
$0.0176 | $0.0176 | $0.0176 | $0.0233 | $0.0176 | 5,290 | 04-05-2024 |
$0.0176 | $0.0176 | $0.0176 | $0.0176 | $0.0176 | 850 | 04-04-2024 |
$0.0231 | $0 | $0.0231 | $0 | $0 | 10 | 04-03-2024 |
$0.0231 | $0.0154 | $0.0231 | $0.0231 | $0.0154 | 11,795 | 04-02-2024 |
$0.0191 | $0.0191 | $0.0191 | $0.0191 | $0.0191 | 95,000 | 04-01-2024 |
$0.0176 | $0.0177 | $0.0176 | $0.0177 | $0.0176 | 3,323 | 03-29-2024 |
$0.0176 | $0.0177 | $0.0176 | $0.0177 | $0.0176 | 3,323 | 03-28-2024 |
$0.0154 | $0.0154 | $0.0154 | $0.0154 | $0.0154 | 6,119 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...
KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangemen...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangeme...